Literature DB >> 22609005

High plasma thiocyanate levels modulate protein damage induced by myeloperoxidase and perturb measurement of 3-chlorotyrosine.

Jihan Talib1, David I Pattison, Jason A Harmer, David S Celermajer, Michael J Davies.   

Abstract

Smokers have an elevated risk of atherosclerosis but the origin of this elevated risk is incompletely defined, though increasing evidence supports a role for the oxidant-generating enzyme myeloperoxidase (MPO). In previous studies we have demonstrated that smokers have elevated levels of thiocyanate ions (SCN(-)), relative to nonsmokers, and increased thiol oxidation, as SCN(-) is a favored substrate for MPO, and the resulting hypothiocyanous acid (HOSCN) targets thiol groups rapidly and selectively. In this study we show that increased HOSCN formation by MPO diminishes damage to nonthiol targets on both model proteins and human plasma proteins. Thus high SCN(-) levels protect against HOCl- and MPO-mediated damage to methionine, tryptophan, lysine, histidine, and tyrosine residues on proteins. Furthermore, levels of the HOCl-mediated marker compound 3-chlorotyrosine and the cross-linked product dityrosine are decreased. Plasma protein 3-chlorotyrosine levels induced by HOCl exposure in nonsmokers are elevated over the levels detected in smokers when exposed to identical oxidative insult (P<0.05), and a strong inverse correlation exists between plasma SCN(-) levels and 3-chlorotyrosine concentrations (r=0.6182; P<0.0001). These correlations were also significant for smokers (r=0.2724; P<0.05) and nonsmokers (r=0.4141; P<0.01) when analyzed as individual groups. These data indicate that plasma SCN(-) levels are a key determinant of the extent and type of protein oxidation induced by MPO on isolated and plasma proteins and that smoking status and resulting high SCN(-) levels can markedly modulate the levels of the widely used biomarker compound 3-chlorotyrosine.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609005     DOI: 10.1016/j.freeradbiomed.2012.04.018

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  20 in total

1.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

Review 2.  Biochemical mechanisms and therapeutic potential of pseudohalide thiocyanate in human health.

Authors:  Joshua D Chandler; Brian J Day
Journal:  Free Radic Res       Date:  2015-01-28

3.  Thiocyanate supplementation decreases atherosclerotic plaque in mice expressing human myeloperoxidase.

Authors:  P E Morgan; R P Laura; R A Maki; W F Reynolds; M J Davies
Journal:  Free Radic Res       Date:  2015-03-27

4.  Selenium inhibits renal oxidation and inflammation but not acute kidney injury in an animal model of rhabdomyolysis.

Authors:  Anu Shanu; Ludwig Groebler; Hyun Bo Kim; Sarah Wood; Claire M Weekley; Jade B Aitken; Hugh H Harris; Paul K Witting
Journal:  Antioxid Redox Signal       Date:  2012-10-16       Impact factor: 8.401

5.  Assessment of myeloperoxidase activity by the conversion of hydroethidine to 2-chloroethidium.

Authors:  Ghassan J Maghzal; Katie M Cergol; Sudhir R Shengule; Cacang Suarna; Darren Newington; Anthony J Kettle; Richard J Payne; Roland Stocker
Journal:  J Biol Chem       Date:  2014-01-16       Impact factor: 5.157

6.  Exposure of aconitase to smoking-related oxidants results in iron loss and increased iron response protein-1 activity: potential mechanisms for iron accumulation in human arterial cells.

Authors:  Jihan Talib; Michael J Davies
Journal:  J Biol Inorg Chem       Date:  2016-02-02       Impact factor: 3.358

7.  The myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitors.

Authors:  Veronika Binder; Senka Ljubojevic; Johannes Haybaeck; Michael Holzer; Dalia El-Gamal; Rudolf Schicho; Burkert Pieske; Akos Heinemann; Gunther Marsche
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-14       Impact factor: 8.311

Review 8.  Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.

Authors:  Cédric Delporte; Pierre Van Antwerpen; Luc Vanhamme; Thierry Roumeguère; Karim Zouaoui Boudjeltia
Journal:  Mediators Inflamm       Date:  2013-07-24       Impact factor: 4.711

9.  Simultaneous determination of 3-chlorotyrosine and 3-nitrotyrosine in human plasma by direct analysis in real time-tandem mass spectrometry.

Authors:  Yuqiao Song; Jie Liao; Cheng Zha; Bin Wang; Charles C Liu
Journal:  Acta Pharm Sin B       Date:  2015-08-29       Impact factor: 11.413

10.  Measuring myeloperoxidase activity in biological samples.

Authors:  Benjamin Pulli; Muhammad Ali; Reza Forghani; Stefan Schob; Kevin L C Hsieh; Gregory Wojtkiewicz; Jenny J Linnoila; John W Chen
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.